BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 10, 2010
 |  BioCentury  |  Strategy

A bargain platform boost

Intercell acquires ability to develop anti-infective mAbs in-house from Cytos

Intercell AG has used its Antigen Identification Program to discover antigens for vaccines and antibodies, but has had to license the latter out to other companies. By spending a modest sum to acquire antibody discovery technology from Cytos Biotechnology Ltd., Intercell is now able to generate its own mAbs against internally discovered targets, a capability it has been seeking for some time.

In 2006, Intercell granted Merck & Co. Inc. rights to develop mAbs against a cell surface protein on Staphylococcus aureus, which also is the antigen in a vaccine the partners have in Phase II/III testing.

That same year, Intercell granted Kirin Brewery Co. Ltd. (now Kyowa...

Read the full 545 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >